Rheumatoid Arthritis

Among all groups, fewer men with rheumatic disease were childless compared with controls.

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A study presented at EULAR 2024 found a positive correlation between RA disease activity levels and mood disorders.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

Two patients with autoimmune diseases from 2 phase ½ RESET trials had complete B cell depletion within 15 days post-infusion with CABA-201 and needed no additional medication.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

Daniel Blockmans, MD, PhD, discussed the results of a phase 3 trial that revealed upadacitinib significantly improved outcomes in patients with giant cell arteritis.

Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.

These findings, presented at RAD 2024, highlight risk of atopic dermatitis patients for developing various cancers as well as major adverse cardiovascular events.

Some of the risk factors for RA-interstitial lung disease include male sex, older age, and smoking history, a study found.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.

Among included RA studies, 83.3% showed significantly better clinical outcomes in patients managed with a T2T strategy compared with usual care.

As the severity of rheumatoid arthritis disease activity increases, so does the prevalence of depression, a new study found.

Age, chronic comorbidities, and COVID-19 vaccination status in patients with IMIDs serve as risk factors for severe COVID-19 outcomes.

E. Michael Lewiecki, MD, discusses the significant treatment gap seen in osteoporosis and barriers to care.